Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 SynlogicLeap TherapeuticsOtonomyZynerba PharmaceuticalsAytu Biopharma
SymbolNASDAQ:SYBXNASDAQ:LPTXNASDAQ:OTICNASDAQ:ZYNENASDAQ:AYTU
Price Information
Current Price$3.09$1.62$2.29$3.82$6.45
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.51.71.31.4
Analysis Score3.43.53.53.41.5
Community Score2.72.62.62.72.6
Dividend Score0.00.00.00.00.0
Ownership Score0.80.81.70.01.7
Earnings & Valuation Score1.30.60.60.61.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$13.25$5.38$8.30$13.65$7.00
% Upside from Price Target328.80% upside231.79% upside262.45% upside257.33% upside8.53% upside
Trade Information
Market Cap$120.56 million$98.44 million$110.65 million$158.00 million$115.17 million
Beta2.21.352.312.83-0.26
Average Volume1,019,936852,8711,122,1424,833,654702,180
Sales & Book Value
Annual Revenue$2.22 millionN/A$600,000.00$90,000.00$27.63 million
Price / Sales55.20N/A184.421,750.924.17
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.86 per share($0.07) per share$1.31 per share$3.26 per share$7.88 per share
Price / Book0.64N/A1.751.170.82
Profitability
Net Income$-51,370,000.00$-32,900,000.00$-44,670,000.00$-32,940,000.00$-13,620,000.00
EPS($1.70)($1.47)($1.45)($1.50)N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,761.83%N/A-14,379.87%N/A-32.73%
Return on Equity (ROE)-41.64%-89.24%-108.75%-60.20%-25.20%
Return on Assets (ROA)-34.39%-70.07%-54.62%-52.40%-13.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.20%N/A0.12%
Current Ratio16.42%8.70%8.97%6.54%3.04%
Quick Ratio16.42%8.70%8.97%6.54%2.51%
Ownership Information
Institutional Ownership Percentage39.53%41.90%72.25%25.99%89.77%
Insider Ownership Percentage17.95%25.89%16.10%11.10%6.60%
Miscellaneous
Employees7230562675
Shares Outstanding39.66 million59.66 million48.32 million41.25 million17.88 million
Next Earnings Date5/14/2021 (Estimated)5/13/2021 (Estimated)5/6/2021 (Estimated)5/10/2021 (Estimated)5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Aytu BioPharma Stock Appears To Be Significantly OvervaluedAytu BioPharma Stock Appears To Be Significantly Overvalued
ca.finance.yahoo.com - April 18 at 9:08 AM
Aytu Biopharma, Inc. (NASDAQ:AYTU)’s Stock Price Slump Recently, But There Still Be Trouble AheadAytu Biopharma, Inc. (NASDAQ:AYTU)’s Stock Price Slump Recently, But There Still Be Trouble Ahead
stocksregister.com - April 17 at 1:15 PM
Aytu Biopharma adds rare disease asset AR101 from Rumpus TherapeuticsAytu Biopharma adds rare disease asset AR101 from Rumpus Therapeutics
seekingalpha.com - April 14 at 1:26 AM
Denovos Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharmaDenovo's Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma
prnewswire.com - April 13 at 10:23 AM
Aytu BioPharma, Inc.: Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus TherapeuticsAytu BioPharma, Inc.: Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
finanznachrichten.de - April 12 at 12:29 PM
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus TherapeuticsAytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
finance.yahoo.com - April 12 at 12:29 PM
Aytu BioPharma, Inc.: Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial OfficerAytu BioPharma, Inc.: Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer
finanznachrichten.de - April 7 at 7:17 AM
Aytu BioPharma Sells U.S. Rights For Natesto To Acerus Pharma; Street Sees 131.5% UpsideAytu BioPharma Sells U.S. Rights For Natesto To Acerus Pharma; Street Sees 131.5% Upside
finance.yahoo.com - April 2 at 7:46 AM
Cantor Fitzgerald Comments on Aytu Biopharma, Inc.s FY2021 Earnings (NASDAQ:AYTU)Cantor Fitzgerald Comments on Aytu Biopharma, Inc.'s FY2021 Earnings (NASDAQ:AYTU)
americanbankingnews.com - April 1 at 8:42 AM
Aytu Biopharma, Inc. (NASDAQ:AYTU) Short Interest Up 60.1% in MarchAytu Biopharma, Inc. (NASDAQ:AYTU) Short Interest Up 60.1% in March
americanbankingnews.com - March 31 at 7:18 AM
Cantor Fitzgerald Initiates Coverage on Aytu Biopharma (NASDAQ:AYTU)Cantor Fitzgerald Initiates Coverage on Aytu Biopharma (NASDAQ:AYTU)
americanbankingnews.com - March 29 at 5:26 PM
NEOS Stock Price Increases Over 60% Pre-Market: Why It HappenedNEOS Stock Price Increases Over 60% Pre-Market: Why It Happened
pulse2.com - March 18 at 9:58 AM
Why Are Neos Therapeutics, Aytu BioScience Stocks Soaring Today?Why Are Neos Therapeutics, Aytu BioScience Stocks Soaring Today?
finance.yahoo.com - March 18 at 9:58 AM
Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote "FOR" the Pending Merger With Aytu BioScienceGlass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote "FOR" the Pending Merger With Aytu BioScience
marketwatch.com - March 12 at 4:17 PM
Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos ...Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos ...
apnews.com - March 12 at 11:17 AM
Aytu Bioscience, Inc. (AYTU) Moves 9.2% Higher: Will This Strength Last?Aytu Bioscience, Inc. (AYTU) Moves 9.2% Higher: Will This Strength Last?
finance.yahoo.com - March 12 at 11:17 AM
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote "FOR" the Pending Merger With Aytu BioScienceLeading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote "FOR" the Pending Merger With Aytu BioScience
marketwatch.com - March 11 at 2:01 PM
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote ...Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote ...
apnews.com - March 11 at 9:01 AM
Aytu BioScience Stock Is Trading Higher After Healight Therapy Shows Improved Outcome In COVID-19 PatientsAytu BioScience Stock Is Trading Higher After Healight Therapy Shows Improved Outcome In COVID-19 Patients
finance.yahoo.com - March 9 at 5:51 PM
AYTU Stock Price Increases Over 15% Pre-Market: Why It HappenedAYTU Stock Price Increases Over 15% Pre-Market: Why It Happened
pulse2.com - March 9 at 12:50 PM
Aytu BioScience, Inc.: Aytu BioScience Announces Positive Clinical Results from Healight Pilot Study in SARS-CoV-2 PatientsAytu BioScience, Inc.: Aytu BioScience Announces Positive Clinical Results from Healight Pilot Study in SARS-CoV-2 Patients
finanznachrichten.de - March 8 at 8:10 PM
Aytu BioScience Reports Positive Results From Healight Pilot Study In SARS-CoV-2 PatientsAytu BioScience Reports Positive Results From Healight Pilot Study In SARS-CoV-2 Patients
nasdaq.com - March 8 at 8:10 PM
Aytu BioScience, Inc.: Aytu BioScience to Present at Upcoming March Investor ConferencesAytu BioScience, Inc.: Aytu BioScience to Present at Upcoming March Investor Conferences
finanznachrichten.de - February 24 at 8:27 AM
Aytu BioScience to Present at Upcoming March Investor ConferencesAytu BioScience to Present at Upcoming March Investor Conferences
finance.yahoo.com - February 24 at 8:27 AM
A Quick Analysis On Aytu BioSciences (NASDAQ:AYTU) CEO SalaryA Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Salary
finance.yahoo.com - February 14 at 8:16 AM
DateCompanyBrokerageAction
3/25/2021SynlogicSVB LeerinkBoost Price Target
3/24/2021SynlogicJonestradingInitiated Coverage
1/13/2021SynlogicChardan CapitalBoost Price Target
8/10/2020SynlogicHC WainwrightReiterated Rating
5/10/2020SynlogicOppenheimerReiterated Rating
11/13/2019SynlogicPiper Jaffray CompaniesReiterated Rating
8/21/2019SynlogicCitigroupDowngrade
8/9/2019SynlogicWedbushReiterated Rating
3/23/2021Leap TherapeuticsRaymond JamesSet Price Target
7/19/2020Leap TherapeuticsLADENBURG THALM/SH SHReiterated Rating
6/29/2020Leap TherapeuticsPiper SandlerInitiated Coverage
2/10/2020Leap TherapeuticsRobert W. BairdInitiated Coverage
8/17/2020OtonomyCantor FitzgeraldReiterated Rating
5/29/2020OtonomyCraig HallumInitiated Coverage
8/14/2018OtonomySunTrust BanksLower Price Target
3/10/2021Zynerba PharmaceuticalsRoth CapitalLower Price Target
2/5/2021Zynerba PharmaceuticalsCanaccord GenuityReiterated Rating
9/14/2020Zynerba PharmaceuticalsNeedham & Company LLCReiterated Rating
9/16/2019Zynerba PharmaceuticalsJefferies Financial GroupReiterated Rating
11/15/2019Aytu BiopharmaNorthland SecuritiesInitiated Coverage
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.